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Abstract
Reproducing the characteristics and the functional responses of the blood–brain barrier (BBB) in vitro represents an
important task for the research community, and would be a critical biotechnological breakthrough. Pharmaceutical and
biotechnology industries provide strong demand for inexpensive and easy-to-handle in vitro BBB models to screen novel
drug candidates. Recently, it was shown that canonical Wnt signaling is responsible for the induction of the BBB properties
in the neonatal brain microvasculature in vivo. In the present study, following on from earlier observations, we have
developed a novel model of the BBB in vitro that may be suitable for large scale screening assays. This model is based on
immortalized endothelial cell lines derived from murine and human brain, with no need for co-culture with astrocytes. To
maintain the BBB endothelial cell properties, the cell lines are cultured in the presence of Wnt3a or drugs that stabilize b-
catenin, or they are infected with a transcriptionally active form of b-catenin. Upon these treatments, the cell lines maintain
expression of BBB-specific markers, which results in elevated transendothelial electrical resistance and reduced cell
permeability. Importantly, these properties are retained for several passages in culture, and they can be reproduced and
maintained in different laboratories over time. We conclude that the brain-derived endothelial cell lines that we have
investigated gain their specialized characteristics upon activation of the canonical Wnt pathway. This model may be thus
suitable to test the BBB permeability to chemicals or large molecular weight proteins, transmigration of inflammatory cells,
treatments with cytokines, and genetic manipulation.
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Introduction
The blood brain barrier (BBB) is a highly specialized region of
the vascular tree, which preserves the integrity of the nervous
system by limiting the passage of harmful substances and
inflammatory cells into the brain [1,2,3]. The endothelial cells
(EC) of the brain microvessels acquire a set of specialized
functional and morphological properties through their interactions
with the surrounding astrocytes and pericytes. This cross talk
between the cells is vital to the functionality of the BBB. The brain
EC, astrocytes and pericytes in close contact form the so-called
‘neurovascular unit’. These EC develop highly selective barrier
functions due to a particularly complex inter-endothelial tight
junction network and a unique set of transporters, which allow the
controlled passage of nutrients and eliminate toxic substances [4].
However, the neuroprotective functions of the BBB hinder the
delivery of many potentially important diagnostics and therapeutic
drugs to the central nervous system. Large molecules, such as
antibodies, and the majority of small molecule drugs cannot cross
the BBB [5,6]. This has dramatically delayed the progress of
pharmacotherapies and immunotherapies in brain diseases.
Furthermore, treatment of neurological disorders, such as multiple
sclerosis, stroke and Alzheimer’s disease, is hindered by the
negligible bioavailability of drugs [7,8,9].
The reproduction of the characteristics and the functional
responses of the brain microvasculature in vitro represents an
important task for the research community and would provide a
critical biotechnological breakthrough. Thus, a crucial need for
the progress in this area is a standardized in vitro assay that can be
shared by many different laboratories to provide comparable
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results. Indeed, an optimal BBB system for large scale screening
needs to be highly reproducible among laboratories, relatively
inexpensive and easy to handle. To date, none of the available
systems fits all of these criteria (for reviews see [10,11,12,13]).
One major problem is that, when they are isolated from the
brain microenvironment, the EC lose their specialized barrier
characteristics in few days. This appears to be due to the
disruption of the brain neurovascular unit, which maintains the
specialized characteristics of EC only through a continuous cross
talk of these cells with astrocytes, pericytes and neurons.
To avoid the loss of endothelial BBB properties, freshly isolated
brain endothelium and astrocytes have been co-cultured in a two
chamber cell culture system. Under these conditions, EC maintain
some of their BBB properties. However, although valuable for
short term analysis, this experimental model is not easily
reproducible and can give variable results from one investigator
to another, which prevents its use on any large scale basis (for
reviews see [10,11,12,13]). Therefore, further efforts are needed to
replace astrocytes with a standardized medium that contains the
factors necessary to maintain the BBB characteristics of brain EC.
In previously published studies [14,15,16], it was demonstrated
that canonical Wnt signaling has a critical role in brain
vascularization and in differentiation of the BBB in vivo. Canonical
Wnt signaling is mediated by b-catenin, which, when is stabilized
in the cytoplasm, can translocate to the nucleus and, through the
interaction with lymphoid enhancer factor/T-cell factor (Lef/Tcf)
transcription factors, modulates gene transcription.
In the present study, we have taken advantage of these early
studies to investigate and define a novel BBB model in which the
addition of Wnt ligands or drugs that increase canonical Wnt
signaling can maintain, and even restore, the BBB properties of
EC in a way similar to that of astrocyte co-cultures. The BBB
properties can be maintained also by infecting the EC with a
dominant active form of b-catenin that can sustain Wnt signaling
in these cells [16].
Even if avoidance of the need for astrocyte co-culture is already
an important standardization step, the use of freshly isolated
primary brain EC cultures is still expensive, time consuming and
requires operator expertise. For this reason, we used immortalized
mouse brain derived microvascular EC as candidate BBB model
[17,18], and we show that this cell line provides an easy-to-handle
model that maintains a number of phenotypic characteristics of
the BBB EC in culture. Upon activation of the canonical Wnt
signaling, these cells show increased BBB marker expression,
including tight junction and adherens junction proteins. Further-
more, as cell monolayers, they show increased transendothelial
electrical resistance (TEER) and reduced permeability, thus
reproducing to a good extent the phenotype of the freshly isolated
brain EC. In addition, similar data were obtained with the
hCMEC/D3 human brain EC line [19].
In conclusion, the strategy described here provides a standard-
ized approach to the preparation of in vitro models of the BBB that
reproduce and maintain the specialized properties of the brain
endothelium.
Results
As a readout for the functional BBB properties, we first defined
a set of genes known to be specifically expressed by freshly isolated
brain EC, as listed in Table 1 (for reviews on BBB markers see
[20,21,22]). A microfluidic card (Custom TaqMan Array; see
Materials and Methods) containing the selected gene probes,
which we refer to as the ‘BBB signature’, was developed and used
systematically for comparisons of cell lines and culture conditions.
An important requirement in the development of a widely
reproducible BBB model system is the use of immortalized EC
lines. Using the BBB-specific gene expression card, we compared
immortalized mouse EC lines derived from the heart microvas-
cular endothelium (H5V cells) [23], the lung endothelium [24] and
the brain endothelium (bEnd5 cells) [17,18] to freshly isolated
mouse brain microvascular endothelial cells (MBMECs) [25,26]
(Figure 1A). The data in the boxplot of Figure 1A are given as a
quality index that summarizes the overall expression of the
selected BBB EC genes as a single value, in comparison with that
of MBMECs (see Materials and Methods). The precise values for
the individual genes are reported in Figure S1A. Figure 1A shows
that the gene expression pattern of bEnd5 cells was close to the
reference MBMECs, which were here normalized to 1. Further-
more, bEnd5 cells show higher expression of tight junction
proteins (Claudin-3, 25, 212) and transporters (such as Slc7a1,
Abcb1b) than H5V cells and lung EC (Figure S1A). Importantly,
we found that the choice of the growth medium used strongly
influences the functional properties of bEnd5 cells. The cells were
cultured with complete Dulbecco’s modified Eagle’s medium
(DMEM) or MCDB-131 for a few passages until confluence, and
the monolayers were compared at the optical microscope. Indeed,
as shown in Figure S2, for bEnd5 cells, most of the BBB-associated
genes were expressed at higher levels when the EC were cultured
in MCDB-131 medium, as compared to DMEM (see Materials
and Methods).
As well as marker gene expression, bEnd5 cells can also
correctly organize their tight junction proteins (Claudin-3, 25)
and adherens junction proteins (data not shown) at cell-to-cell
contacts to comparable levels of MBMECs.
From these initial studies, among the immortalized cell lines
tested, bEnd5 cells appeared to be a good candidate to reproduce
the BBB EC characteristics. However, bEnd5 cells did not
reproduce the same gene expression pattern or show the same
control of cell permeability (see below) as the freshly isolated
MBMECs. (Figure 2B, Figure S3).
In earlier studies [14,15,16], it was reported that canonical Wnt
signaling is responsible for the induction of the BBB properties
during brain vascularization in the embryo and in newborn mice.
The canonical Wnt pathway, which is induced by Wnt3a or
Wnt7a/b in the brain, acts via b-catenin stabilization in the
cytosol, which favors the nuclear translocation of b-catenin and its
binding to transcription factors of the Lef/Tcf family [27]. We
therefore tested whether activation of bEnd5 cells by Wnt3a can
restore high expression levels of the BBB EC genes. As shown in
Figure 1B, various conditions were tested; i.e., conditioned
medium from Wnt3a-transfected L-cells (Wnt3aCM), and two
different recombinant Wnt3a preparations (Figure 1B, Peprotech
and R&D [28]). bEnd5 cells cultured in undiluted Wnt3aCM
significantly increased the expression of the BBB-specific genes
and the application of two different recombinant preparations of
Wnt3a had comparable effects, or was slightly less effective
(Figure 1B). The single gene variations are shown in Figure S1B.
Figure S4 shows immunofluorescence staining of bEnd5 confluent
monolayers under controlCM and Wnt3aCM conditions. Inter-
estingly, Wnt3a up-regulates the junctional expression of Claudin-
3 but not of Claudin-5 in bEnd5 cells to a comparable level of
MBMECs. As expected, active (unphosphorylated) b-catenin
translocates to the nucleus upon Wnt3a activation, while
junctional VE-cadherin is unchanged, as compared to the
MBMECs (Figure S5). Altogether, these data support the concept
that canonical Wnt signaling can restore and maintain the BBB
EC properties both in the bEnd5 cells and the freshly isolated
MBMECs.
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However, although these data are encouraging, these observa-
tions are still insufficient for the development of a standardized
BBB model that can be reproducibly used for large scale screening
assays in different laboratories. The conditioned medium from the
Wnt3a transfected cells still needs to be titrated, and the
concentration of Wnt3a might vary greatly among different
preparations (see Materials and Methods). Recombinant Wnt3a
preparations are also relatively expensive and cannot be used for
large scale experiments.
We therefore tested whether we could substitute Wnt3a with
chemicals that act by increasing canonical Wnt signaling through
inhibition of GSK3a/b, which is responsible for b-catenin
phosphorylation and degradation [29,30,31]. To this end, we
compared four different GSK3b inhibitors: lithium chloride (LiCl)
[32], SB216763 [33], and (29Z, 39E)-6-Bromo-indirubin-39-oxime
(BIO) and its acetoxime analog (29Z, 39E)-6-Bromo-indirubin-39-
acetoxime (BIO-Acetoxime, 6-BIO) [34,35]. LiCl and SB216763
inhibit b-catenin phosphorylation and degradation in the protea-
some, while BIO and 6-BIO are cell-permeant compounds that
are selective and reversible ATP-competitive inhibitors of
GSK3a/b [34,35,36]. Of note, 6-BIO has greater selectivity for
GSK3a/b and, importantly, is less cytotoxic at higher concentra-
tions than BIO (see Merck’s specifications).
As shown in Figure S6, BIO and 6-BIO treatment increased
BBB-specific gene expression more efficiently than LiCl and
SB216763. BIO and 6-BIO treatments were also more compara-
ble to Wnt3a treatment (Figure S1B), although they showed lower
effects. The pie diagram in Figure S6 indicates that the BIO-
activated and 6-BIO-activated bEnd5 monolayers have the highest
expression levels under each condition, when expressed as the
percentages of genes. The comparison of BIO, 6-BIO, Wnt3aCM
and recombinant preparations of Wnt3a showed that, under all
conditions, expression of the BBB endothelial cell specific genes
was increased (Figure 1B).
To further standardize and simplify the procedure, we infected
bEnd5 cells with a lentiviral construct that expresses a fusion
protein containing the transactivation domain of b-catenin and a
truncated form of the LEF-1 protein (LEFDN-bCTA). This
chimera cannot associate to cadherins, but retains its transcrip-
tional activity [37]. In other words, this condition reproduces
constant cell activation by canonical Wnt signaling.
As shown in Figure 1B and in Figure S1B, the LEFDN-bCTA
bEnd5 cells (+b-CTA) showed a level of expression of the BBB
endothelial cell-specific genes that was comparable to the
MBMECs and to bEnd5 cells treated with the Wnt3aCM. This
LEFDN-bCTA infection was also more effective than the BIO and
6-BIO treatments (Figure 1B). As with the MBMECs, immuno-
fluorescence analysis confirmed the up-regulation of junctional
Claudin-3 in these LEFDN-bCTA bEnd5 cell monolayers, similar
to that seen for Wnt3a and BIO activation (+b-CTA, Figure S4).
An optimal BBB EC model must also show high TEER and
restrictive paracellular permeability. Therefore, we performed
studies to test these parameters on the bEnd5 cell monolayers by
comparing the different conditions described above. We measured
the impedance continuously over a period of ,190 hours for
MBMECs and bEnd5 transduced with or without LefDN-bCTA
(Figure 2A). MBMECs showed the absolute highest TEER of
,65V.cm2, ,43 hours after plating and subsequent attachment,
indicated by the lowest Ccl values. But importantly, also bEnd5
cells transduced with LefDN-bCTA (bCTA-bEnd5) exhibited a
pronounced increase in TEER over the GFP controls. It is worth
noting that at late times (125 hours) after media exchange, bCTA-
bEnd5 recovered more robustly than the MBMECs, suggesting
that bCTA-bEnd5 are suitable for long-term cultures. In order to
statistically analyse TEER data we show values at 24, 48 and 72
hours for the different conditions after the EC monolayers had
reached confluence as % of control (Figure 2B,C) (see Materials
and Methods). The monolayers of parental bEnd5 cells showed
significantly lower barrier properties in comparison to the primary
MBMECs, as evidenced by the higher TEER and lower
capacitance (Ccl, as indication for an adequate intact cell culture
barrier) in the MBMECs (Figure 2B, Figure 3S). The monolayers
of bCTA-bEnd5 boosted the barrier properties, as indicated by an
increased TEER when compared to control cells (GFP infected
bEnd5, GFP-bEnd5) and a concomitant reduction in the Ccl
(Figure 2C, Figure 3S), bringing these values closer to those of the
primary MBMECs. Monolayers of bEnd5 cells treated with the
GSK3a/b inhibitor 6-BIO showed significant effects in terms of
improved TEER and decreased Ccl, as compared to the DMSO-
Table 1. BBB endothelial signature genes.
Gene Probe Description
Cdh5/VE-cadherin [50,51] Mm00486938_m1 Adherens junctions, Cadherin-5, vascular endothelium (VE)-cadherin
Cldn3 [52,53,54] Mm00515499_s1 Tight junctional Claudin-3
Cldn5 [54,55] Mm00727012_s1 Tight junctional Claudin-5
Cldn12 [53,56] Mm01316510_m1 Tight junctional Claudin-12
Plvap/PV-1 [57,58] Mm00453379_m1 Plasmalemma-vesicle-associated protein
Bsg/HT-7/CD147 [59,60] Mm01169115_m1 Leukocyte activation antigen M6, Basigin
Slc2a1/Glut1 [61,62] Mm00441473_m1 Solute carrier family 2/Facilitated glucose transporter 1
Slc7a1/CAT1 [63,64] Mm00432019_m1 Solute carrier family 7/Cationic amino acid transporter 1
Abcg2/BCRP [65,66] Mm00496364_m1 ATP-binding cassette transporter G2
Abcc4/MRP4 [67,68] Mm01226381_m1 Multidrug-resistance-associated protein 4
Abcb1b/MDR1/P-gp [69,70] Mm00440736_m1 Multidrug-resistance protein 1
Lrp1/A2MR/APOER [71,72] Mm00464608_m1 Low-density lipoprotein receptor-related protein 1
Ager/RAGE [72,73] Mm01134790_g1 Receptor for advanced glycosylation end products
Gpr126 [74] Mm01193801_m1 G-protein coupled receptor 126
doi:10.1371/journal.pone.0070233.t001
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treated control (Figure 2D). Importantly, when bEnd5 cells were
co-cultured with astrocytes (Figure 2E, +AC), the absolute values
of TEER were close to those of cells treated with BIO but lower
than those of MBMECs or bCTA-bEnd5 (Figure 2E, 2AC).
We then measured the permeability of endothelial monolayers
to 38kDa FITC-dextran, reported as relative fluorescence units
(RFUs) (Figure 3A,B). Monolayers of bCTA-bEnd5 showed a
lower dextran flux at all times measured, as compared with the
control GFP-infected cell line (Figure 3A). Furthermore, mono-
layers of bEnd5 cells treated with the Wnt3aCM showed lower
values for this dextran flux, as compared to the control (Figure 3B).
Notably, parental- and GFP-infected bEnd5 monolayers did not
differ significantly in impedance measurements (data not shown).
Taken together, our data show that the bCTA-bEnd5 cell line
constitutes a reproducible model system of BBB. As this model is
based on an immortalized cell line, it can be maintained in culture
Figure 1. Box plots showing the genetic comparisons between immortalized mouse endothelial cell lines and primary brain
microvascular endothelium as reference. A. Global distribution of the BBB-specific genes in the bEnd5, H5V and lung cells in comparison with
MBMECs (set to 1; dotted line). A non-parametric test (i.e., Wilcox test, alpha value set at 0.05) was used to determine whether or not the differences
between these cell types are significant. *p,0.1; **p,0.05; n.s., not significant. B. Global distribution of the BBB-specific genes in the bEnd5 cell
systems, compared with MBMECs (set to 1; dotted line). Various conditions were tested: conditioned medium from Wnt3a-transfected L-cells
(Wnt3aCM) undiluted (pure) or diluted 1 to 3 in growing medium; two different commercial recombinant Wnt3a preparations (100 ng/ml; Peprotech
and R&D); BIO and 6-BIO (2.5 mM). Undiluted Wnt3aCM treatment was for 3 days (first boxplot from the left) or 24 hours (second boxplot from the
left), as all the other cell activations. b-CTA (cells infected with LEFDN-bCTA) and +Astros (co-culture with astrocytes). No significance differences were
detected between these conditions, although a negative trend was seen for R&D Wnt3a and BIO conditions, as median values are lower than 1.
doi:10.1371/journal.pone.0070233.g001
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for extended times and numbers of passages. The culture
conditions require a standard medium, and the parameters
reported above have been reproduced over two years in the three
separate laboratories that have contributed to this study. The
functional parameters and BBB EC gene expression is comparable
to freshly isolated MBMECs and to co-culture of the parental cell
line with astrocytes.
The bCTA-bEnd5 cell system appears to be particularly suited
for large scale BBB EC screening assays, as these cells do not need
additional expensive reagents (e.g., Wnt recombinant proteins) or
complex co-culture systems.
To test whether we can extend these observations to the
hCMEC/D3 immortalized human brain microvascular EC line
[19], we activated these cells with LiCl to stabilize b-catenin, and
checked for the expression of some of the BBB endothelial cell
related genes (Figure 4A,B). This treatment induced the up-
regulation of the tight junction proteins Claudin-3 and Claudin-5
and the transporter Abcg2, while the other selected markers were
non-significantly modified likely because they were already rather
high without cell activation by LiCl (Figure 4A,B). LiCl and
Wnt3aCM reduced permeability of the hCMEC/D3 cells to
Lucifer Yellow (Figure 4C, Pe). In contrast the b-catenin
antagonist XAV939, an Axin 2 stabilizer [38], increased
permeability alone and in combination with LiCl (Figure 4D).
We conclude from these data that activation of canonical Wnt
signaling may be a general strategy to optimize in vitro models of
the BBB of various species.
Figure 2. b-catenin transcriptional activity improves impedance of bEnd5 cells A–D. Transendothelial electrical resistance (TEER, top
panels) and the corresponding capacitance (Ccl, bottom panels) of the endothelial monolayers at various times after they reached confluence. A.
Representative TEER/Ccl measurement comparing MBMECs, bEnd5 and bEnd5 infected with LEFDN-bCTA (bCTA-bEnd5), indicating that b-catenin
transcriptional activation leads to increased electrical resistance in bEnd5 cells. Vertical line at 125 hours indicates media exchange and boxed insert
shows magnification of the Ccl curves after the media exchange, highlighting pronounced lower values for the bCTA-bEnd5 compared to bEnd5
controls. B. Parental bEnd5 cells in comparison to the primary mouse MBMECs cells (n = 3). C. bEnd5 cells infected with lenti-LEFDN-bCTA in
comparison to the lenti-GFP control. D. bEnd5 cells treated with the GSK3a/b inhibitor 6-BIO (2.5 mM) in comparison to the DMSO-treated cells. E.
bEnd5 cells co-cultured with astrocytes (+AC) in comparison to bEnd5 cell monocultures (2AC).
doi:10.1371/journal.pone.0070233.g002
Wnt-Dependent BBB Model In Vitro
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e70233
Discussion
In the present study, we propose a novel method to optimize in
vitro BBB model systems. The method is based on activation of the
canonical Wnt/b-catenin pathway of immortalized brain micro-
vascular EC lines of mouse (bEnd5) and human origin (hCMEC/
D3).
Previously, we and others have reported that canonical Wnt
signaling directs brain angiogenesis during embryo development,
and at a later step, induces BBB differentiation [14,15,16]. The
continuous cross talk of EC and astrocytes is necessary to maintain
the functional properties of the BBB. When brain EC are isolated
and cultured in the absence of astrocytes, they rapidly lose their
phenotypic properties. So, as astrocytes produce different mem-
bers of the Wnt family, we sought to reconstitute the effects of the
co-culture by addition of Wnt ligands or drugs that reproduce the
Wnt effects. Indeed, we report here that such an approach can
maintain the BBB characteristics of the EC for long periods of time
and through multiple passages in culture, thus establishing an easy
to handle and reproducible model. The readout for the properties
of the BBB used in our study was the pattern of the specific gene
expression and the control of monolayer permeability.
As further standardization of the response, and to avoid the
addition of expensive reagents, we transfected the bEnd5 murine
brain cell line with a mutant of b-catenin that cannot be degraded
and maintains high b-catenin transcriptional activity (LEFDN-
bCTA). The LEFDN-bCTA bEnd5 cell line reproduced, to a
good extent, the characteristics of freshly isolated MBMECs.
Furthermore, the LEFDN-bCTA construct has transcriptional
activity only and lacks interactions with cadherins at junctions.
This excludes the possibility that our results are due to increased b-
catenin levels at adherens junctions.
The hCMEC/D3 immortalized human brain EC line [19]
similarly responded to canonical Wnt activation by the up-
regulation of BBB endothelial cell specific gene expression and
reduced monolayer permeability. Although additional experi-
ments are required to further optimize these experimental settings,
these data strongly suggest that the approach described in the
present study can be extended to other types of brain EC lines,
including human cells.
Others have developed experimental systems using human
brain EC. Bernas and colleagues [39] described a method for the
generation of primary cultures of human brain microvascular EC
derived from temporal tissue microvessels, with the limitation of
individual sample variability and restricted availability (human
brain samples are obtainable only after informed consensus and
consideration by institutional review boards) [39]. This essentially
prevents the use of this model for large scale screening assays.
A recent study described the derivation of EC from human
pluripotent stem cells [40]. Through this procedure, the authors
were able to reproduce the characteristics of the BBB using a co-
differentiation procedure of EC with neural cells. This assay is of
great value for studies of the differentiation steps of the BBB EC,
but it is not suitable for drug screening for the complexity of the
experimental procedure.
In conclusion, activation of the Wnt pathway is a relatively easy
and versatile tool to establish and maintain the BBB properties of
different types of EC in vitro. Although this method still has
limitations, such as the lack of exposure to hemodynamic forces,
the use of immortalized cell lines under standardized culture
conditions makes this assay reproducible across different labora-
tories and suitable for large scale screening assays.
Materials and Methods
Animals
For MBMECs preparation C57Bl6 wild-type 2 months-old
mice were used; for astrocytes preparation 4 days old pups were
used (Charles River Laboratories).
Animal Statement
Mice were housed according to the guidelines set out in
Commission Recommendation 2007/526/EC - June 18, 2007 on
guidelines for the accommodation and care of animals used for
experimental and other scientific purposes. At the end of the
experiment, mice were euthanized by inhalation of high concen-
Figure 3. b-catenin transcriptional activity reduces dextran permeability of bEnd5 cells. A,B. Endothelial monolayer permeability to FITC-
labeled 38-kDa dextran, was measured as percentage (%) of relative fluorescence units (RFUs). A. bEnd5 cells infected with LEFDN-bCTA in
comparison to GFP as control. B. bEnd5 cells treated with Wnt3a conditioned medium (Wnt3aCM) in comparison to the control medium (controlCM).
p values were obtained by a 2-tailed paired t-test (Graphpad Prism 5.0), using values from n=3 independent experiments, and pairing for time points.
doi:10.1371/journal.pone.0070233.g003
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trations of CO2. Procedures involving animals and their care
conformed to institutional guidelines in compliance with national
law and policies (4D.L.N.116, G.U., supplement 40, 18-2-1992)
and approved by the Italian Ministry of Health. All efforts were
made to minimize the number of animals used and their suffering.
EC Isolation and CultureMouse brain microvascular fragments
were processed as previously described [25,26]. Capillary
fragments were seeded on Collagen I (BD Biosciences) coated
wells and cultured in DMEM (Life Technologies)+20% fetal calf
serum (FCS; Hyclone) supplemented with 100 mg/ml heparin
(Sigma) and 5 mg/ml ECGS (EC Growth Supplement, homemade
from calf brain [24]). After 2 days of puromycin selection (4 mg/
ml) cells were exposed for 4–5 days to conditioned medium of L-
cells producing Wnt3a as described [16] (Wnt3aCM, controlCM).
Immortalized mouse EC were isolated and cultured as
previously described [24]. Briefly, lung EC were grown on 0.1%
Figure 4. LiCl treatment improves the BBB-specific phenotype of hCMEC/D3 cells. A. Basal mRNA expression of the BBB endothelial cell-
related genes in hCMEC/D3 cells (as indicated; +++: 20,D2-Ct,25; ++: 25,D2-Ct,30; +: 30,D2-Ct,35). (For details see statistical analysis paragraph
in Materials and Methods). B. qRT-PCR analysis from hCMEC/D3 cells treated with 10 mM LiCl compared with untreated cells. The RNA level obtained
from untreated cells was set to 1 and the ratio LiCl treated versus control is shown for each gene. * p,0.05. Cldn, Claudins; VE-cad, VE-cadherin;
Abcb1b, multidrug resistance protein 1; Abcg2, ATP-binding cassette transporter G2; Slc2a1, Solute carrier family 2 (facilitated glucose transporter) 1.
C. hCMEC/D3 cell permeability (Pe) to Lucifer Yellow. Cells were untreated (EBM2) or treated with controlCM, 50% Wnt 3aCM or 10 mM LiCl (Pe
values normalized to EBM2 Pe= 1.761023 cm/min). D. hCMEC/D3 cell permeability (Pe) to Lucifer Yellow. Cells were incubated with DMSO as control
or 20 mM XAV939 (XAV), 10 mM LiCl, or 10 mM LiCl plus 20 mM XAV939 (LiCl+XAV; Pe values normalized to DMSO Pe=1.6561023 cm/min). All cell
treatments were performed for 6 days.
doi:10.1371/journal.pone.0070233.g004
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gelatin-coated plates in MCDB-131 medium (Life Technolo-
gies)+20% FCS, supplemented with 100 mg/ml heparin, and
5 mg/ml ECGS [24].H5V cell line was originally isolated from the
heart microcirculation of E15 fetus [23,24] and the culture
medium was DMEM+10% FCS, 100 mg/ml heparin and 5 mg/ml
ECGS.
Immortalized brain derived EC, bEnd5 cells [17,18], were
grown on 0.1% gelatin or 5 mg/ml fibronectin (Sigma)-coated
plates, from passage 18 to 25, in MCDB-131 supplemented with
20% FCS, 100 mg/ml Heparin and 5 mg/ml ECGS. In some
experiments, when indicated, bEnd5 were grown in DMEM
supplemented with 10% FCS, 1% nonessential amino acids, as
described in the literature [41].
Immortalized cerebral microvascular EC of human origin,
hCMEC/D3 [19], were plated on the top of 12-well transwell
insert, 0.4 mm pore size (Corning), coated with 150 mg/ml rat tail
collagen type I (R&D Systems). The culture medium was EBM-2
(Lonza) supplemented with 5% FBS (PAA Laboratories GmbH)
10 mM HEPES (PAA Laboratories), 1% chemically defined lipid
concentrate (Invitrogen), 1.4 mM hydrocortisone, 5 mg/ml ascor-
bic acid, and 1 ng/ml bFGF (Sigma). When indicated LiCl,
Wnt3aCM at 50%, XAV939 (Sigma) and DMSO as a control,
were added to the medium for 6 days to activate the cell
monolayers.Culture of Murine Astrocytes
Cerebral cortices from 4 days old mouse pups were isolated in
HBSS (with Ca++ and Mg++; Life Technologies) and digested with
0.05% trypsin/EDTA (Sigma) and 50 mg/ml DNase I (Roche).
Cortical isolates were seeded on 0.001% poly-L-lysine-coated 25-
ml flasks, and maintained in DMEM with 10% FCS. The primary
neuroglia was determined to be .95% pure by glial fibrillary
acidic protein immunoreactivity and fluorescence-activated cell
sorting analysis (FACS) (data not shown).
Reagents and Antibodies
Recombinant Wnt3a (100 ng/ml; R&D systems or Peprotech)
or phosphate-buffered saline (PBS) supplemented with 0.1% FCS
as control; LiCl (10 mM, Sigma), SB216763 (10 mM, Sigma), BIO
(2.5 mM, Merck) and its acetoxime analog 6-BIO (2.5 mM, Merck),
XAV939 (20 mM, Sigma) or DMSO as control. Wnt3aCM [28]
was obtained by culturing L-cells transfected with a murine
Wnt3a-expressing vector (with the parental cell line as control)
(ATCC#CRL-2647 and #CRL-2648) [42]. The controlCM and
Wnt3aCM were added to the cell monolayers either undiluted or
1:3 diluted in growing medium.
Wnt3aCM activity, measured as Axin2 induction, was com-
pared to commercially available recombinant Wnt3a (R&D
systems [28] and Peprotech). A dose response for recombinant
Wnt3a (25, 50, 100, 150 or 200 ng/ml for 24 hours) was tested on
the bEnd5 cell line. The activity of undiluted Wnt3aCM
corresponds to a concentration of around 100 ng/ml of the
purified one confirming what previously reported [42].The
following primary antibodies were used in immunofluorescence:
mouse anti-Claudin-5 (Invitrogen), rabbit anti-Claudin-3 (Invitro-
gen), rat anti-VE-cadherin (clone BV13, e-Bioscience) [43], active-
b-catenin antibody (8E7, Millipore). For secondary detection,
species-specific Alexa Fluor-coupled secondary antibodies were
used.
Co-culture Experiments
To create a ‘close-contact’ co-culture system, astrocytes
(4.56104 cells) were seeded on the basal side of 24-well transwell
insert (0.001% PLL-coated polyester membrane clear, pore size
0.4 mm, Corning). Upon the astrocytes adhesion, 2.06105 bEnd5
cells were seeded on the apical surface of the same insert coated
with fibronectin (5 mg/ml).
Finally the inserts with bEnd5 and astrocytes were transferred
into the outer chamber and the cells were grown in DMEM with
10% FCS. After 3 days of co-culture, the cell monolayers were
either assayed for TEER and Ccl measurements or lysed for RNA
extraction.
RNA Preparation and qRT-PCR
Total RNA was extracted with RNeasy Kit (QIAGEN) and
1 mg was reverse transcribed with random hexamers (High
Capacity cDNA Archive Kit, Applied Biosystems), in accordance
with the manufacturer’s instructions and as described previously
[25]. Micro fluidic card (qPCR cards, Applied Biosystems) was
created for array profiling of the transcripts of the ‘‘BBB
signature’’ genes. cDNA was amplified with the TaqMan Gene
Expression Assay (Applied Biosystems) in an ABI/Prism 7900 HT
thermocycler.
Total RNA from hCMEC/D3 cells was prepared as previously
described [19]. 1 mg was reverse transcribed in a reaction mixture
containing 500 mM of each dNTP, 10 mM DTT, 0.15 mg/ml
random hexamers primers (Amersham Biosciences), 20 U RNase-
OUT (Invitrogen) and 100 U superscript II RNase reverse
transcriptase (Invitrogen). Quantitative RT-PCR SYBR GREEN
fluorescein mix (Roche) was used following the manifacturer’s
instructions. Specific primers for each gene were designed using
the OLIGO 6.42 software (MedProbe). The primer sequences
used are shown in Table S1.
Lentivirus Infection
The lentiviral constructs (Lenti-GFP and Lenti-LEFDN-bCTA),
the viral preparation and infections were previously described
[16,44].
Immunofluorescence Microscopy
The cells cultured in 35 mm diameter Petri dishes or 8-well
chamber slides (Ibidi) were fixed with either 4% paraformaldehyde
for 20 min at room temperature (RT), or with ice-cold methanol
at 220uC for 5 min. Blocking (30 min), primary antibodies
(1 hour, RT) and secondary antibodies (45 min, RT) were either
in PBS with 2.5% skimmed milk and 0.3% TritonX-100 or in 2%
BSA/PBS [45]. Immunofluorescence microscopy was performed
either with Leica TCS AOBS or Nikon C1-si confocal microscopy.
The images produced were processed by Adobe Photoshop and
ImageJ software.
Impedance Measurements
Impedance measurements were performed with a cellZscope
device (nanoAnalytics), according to manufacturer specifications,
using the default frequency protocol, starting at 1 Hz and ending
at 100 kHz, as previously described [46]. The complex impedance
(Z) of the EC monolayer is a function of its TEER and its
capacitance (Ccl). An iteration algorithm was applied to fit the
measured Z values to a parametric function and to calculate
TEER and capacitance Ccl, assuming a parallel circuit of TEER
and capacitance to describe the EC monolayer [47]. The
preparation of EC monolayers for electrical measurements was
similar to the permeability assay set-up (see below), with a few
modifications. Briefly, 105 cells/cm2 (primary cells from passage 0)
or 1.56105 cells/cm2 (as bEnd5 cells at passage 20–25) were
plated on 1.0 mm 24-well polyethylene terephthalate transwell
inserts (Greiner Bio-One) coated with 5 mg/cm2 fibronectin. The
inserts were transferred to the cellZscope instrument and
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measurements were commenced. The medium was changed every
3 days. All of the treatments started after the monolayer reached
confluency, as judged from a plateau in the TEER and Ccl values,
which were typically attained at 72 hours after seeding. For all of
the treatments, the supplemented medium was added to both
apical and basal chambers.
Permeability Assay
Paracellular permeability through the bEnd5 monolayer was
measured as previously described [44]. Briefly, EC were cultured
to confluency on glutaraldehyde-cross-linked gelatin Transwell
units (0.4 mm pore, Corning Costar) for 5 days. 1 mg/ml of 38-
kDa FITC-dextran (Sigma) was added in the apical compartment.
At different times, 50 ml samples were taken from the lower
compartment to measure fluorescence (492/520 nm, absorption/
emission wavelengths) using a Wallac Victor3 1420 multilabel
fluorometer counter (Perkin Elmer).
Paracellular permeability through the hCMEC/D3 monolayer
was measured as already mentioned [19]. The cells were seeded
onto culture inserts for 6 days. At the time of analysis, the culture
medium was replaced with transport buffer (10 mM HEPES,
1 mM sodium pyruvate and HBSS, Invitrogen) in the lower
chamber. In the upper chamber, 50 mM Lucifer Yellow salt in
transport buffer was added. To quantify the tracer passage, the
abluminal compartment was analyzed at each time points using a
fluorometer (Fusion, Packard Bioscience Company) at the
excitation and emission wavelengths of 425 nm and 538 nm,
respectively. Permeability calculations were performed using the
clearance principle, as described by Siflinger-Birnboim and
colleagues [48]. The data are expressed as the permeability
coefficient (Pe) in 1023cm/min or as the percentage of perme-
ability normalized to the permeability coefficient for the control
conditions of untreated cells.
Statistical Analysis
Comparison of candidate cell lines. A genetic comparison
between a given cell line and a reference cell (e.g., freshly isolated
brain primary cells) starts with the development of an RT-PCR
assay for a specific set of genes of interest (Table 1). As a result,
normalized delta-delta Ct values (D2-Ct, one for each gene)
expressing the fold-change in the mRNA expression of the
candidate cell line with respect to the reference cells is obtained.
Furthermore, post-processing analysis of raw Ct data also provides
normal standard errors and standard deviations for the D2-Ct
values. The results obtained in our analysis are shown in Table S1.
The normalization was performed against two housekeeping
genes, 18S and GAPDH, using the normalization method
described in [49].
Given two candidate cell lines, the two corresponding sets of D2-
Ct can be considered (candidate cell lines against reference cell
line), and a non-parametric test can be performed (i.e., Wilcox test,
alpha value set at 0.05), to determine whether or not the difference
between these cells is significant.
Graphically, the candidate cell lines can be compared using
box-plots. These show a horizontal solid line at the half-percentile
(i.e., 50%, the median) of the distribution; the bottom and top
horizontal lines represent the lower and upper quartiles (25% and
75% of the distribution); whiskers, when present, extend to a
maximum of 61.5-times the inter-quartile (i.e., 75% value –25%
value), with values more extreme represented by circles (outliers).
For the bEnd5, H5V and lung EC comparisons, the following
selected BBB genes were included in the analysis: VE-cadherin
(Cdh5), Claudin-3 (Cldn3), Claudin-5 (Cldn5), Claudin-12
(Cldn12), Basigin (Bsg), Plasmalemma-vesicle-associated protein
(Plvap), P-gp (Abcb1b) and Glut-1 (Slc2a1) (See Table 1).
Comparison of different modes of activation of bEnd5
cells. Different GSK3b inhibitors were compared following the
same procedures described previously for comparisons of terrains.
The expression values (D2-Ct) of the signature genes were reported
as a histogram for the different conditions. Due to the
heterogeneity of the results, we further evaluated the percentages
of genes with the highest expression values for each condition and
summarized this information using a pie diagram (see Figure S6).
Comparison of different culture conditions of bEnd5
cells. The two media tested in our study were compared in
terms of expression of the signature genes. We report the
histogram of expression values (in terms of D2-Ct), with the
standard deviations linked to technical replicates. As there were
heterogeneous results for the different genes, we summarized these
by counting the percentage of genes that were better expressed in
one medium with respect to the other. This information is
illustrated in a pie diagram (see Figure S2).
Supporting Information
Figure S1 Genetic comparisons between immortalized
mouse endothelial cell lines with primary brain micro-
vascular endothelium set as reference. A. Histograms of
single gene distributions in the immortalized bEnd5, H5V and
lung cells, in comparison to primary MBMECs (set to 1; red line).
B. Histograms of single gene distributions in the different bEnd5
cell treatments in comparison with primary MBMECs (set to 1;
red line). For all cell treatment details and abbreviations refer to
the Figure legend 1B.
(TIF)
Figure S2 Comparison of bEnd5 cell culture conditions.
Expression levels (D2-Ct) with standard deviations of the technical
replicates of bEnd5 cultured in DMEM or MCDB-131 cell culture
media. The pie diagram shows the percentages of genes that are
better expressed under one condition with respect to the other.
(TIF)
Figure S3 Spectra for a single well from the 3 conditions
depicted in Figure 2A.We have selected the time points 24, 48,
and 72 hours of a single well for each condition that is shown in
Figure 2B as % control TEER and Ccl values. The frequency
protocol for obtaining the total impedance values has been
described in the methods section. Briefly, the impedance values (Z)
for the frequencies between 100–1000 Hz are described to
primarily affect the TEER and Ccl values of endothelial cells. An
increase in the height of the plateau represents an increase in
TEER and an increase in the breadth of the plateau represents a
decrease in Ccl.
(TIF)
Figure S4 Wnt3a pathway activation upregulates the
expression of the tight junction protein Claudin-3 in
bEnd5 cells similarly to primary MBMECs. Immunoflu-
orescence staining for Claudin-3 and Claudin-5 in MBMECs (top-
left panels) and bEnd5 cells (top-right panels) treated with Wnt
3aCM or controlCM for 24 hours. The same stainings are also
performed in bEnd5 cells upon treatment with either BIO or
DMSO as control (bottom-left panels) and upon the infection with
lentivirus expressing LEFDN-bCTA (+bCTA) or GFP as control
(bottom-right panels). Scale bar: 20 mm
(TIF)
Figure S5 Wnt3a pathway activation does not modify
VE-cadherin junctional localization but promotes b-
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catenin nuclear translocation in both bEnd5 and prima-
ry MBMECs. Immunofluorescence staining for active b-catenin
and VE-cadherin both in MBMECs and bEnd5 treated with
Wnt3aCM or controlCM. White arrowheads indicate the nuclear
localization of active b-catenin. Scale bar: 20 mm
(TIF)
Figure S6 Comparison of different GSK3b inhibitors on
cell activation. Expression levels (D2-Ct) of the BBB endothe-
lialcell-specific signature genes under the four different GSK3b
inhibition conditions, as indicated. The pie diagram summarizes
gene heterogeneity and shows the percentages of genes that are
better expressed under one condition in comparison to the others.
(TIF)
Table S1 BBB endothelial cell-specific gene signature
list for human hCMEC/D3 cells (Forward primers, 59–
39; reverse primers, 39–59).
(DOCX)
Table S2 Normalized D2-Ct values for the signature
genes across all of the cell lines.
(DOCX)
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